Abstract
Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Protein & Peptide Letters
Title:Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation
Volume: 19 Issue: 9
Author(s): Yuko Tagaya, Aya Osaki, Atsuko Miura, Shuichi Okada, Kihachi Ohshima, Koshi Hashimoto, Masanobu Yamada, Tetsurou Satoh, Hiroyuki Shimizu and Masatomo Mori
Affiliation:
Keywords: Nucleobindin-2, Nesfatin-1, adipogenesis, 3T3-L1, insulin, GST
Abstract: Nucleobindin-2 is a 420 amino acid EF-hand Ca2+ binding protein that can be further processed to generate an 82 amino terminal peptide termed Nesfatin-1. To examine the function of secreted Nucleobindin-2 in adipocyte differentiation, cultured 3T3-L1 cells were incubated with either 0 or 100 nM of GST, GST-Nucleobindin-2, prior to and during the initiation of adipocyte differentiation. Nucleobindin-2 treatment decreased neutral lipid accumulation (Oil-Red O staining) and expression of several marker genes for adipocyte differentiation (PPARγ, aP2, and adipsin). When Nucleobindin- 2 was constitutively secreted into cultured medium, cAMP content and insulin stimulated CREB phosphorylation were significantly reduced. On the other hand, intracellularly overexpressed Nucleobindin-2 failed to affect cAMP content and CREB phosphorylation. Taken together, these data indicate that secreted Nucleobindin-2 is a suppressor of adipocyte differentiation through inhibition of cAMP production and insulin signal.
Export Options
About this article
Cite this article as:
Tagaya Yuko, Osaki Aya, Miura Atsuko, Okada Shuichi, Ohshima Kihachi, Hashimoto Koshi, Yamada Masanobu, Satoh Tetsurou, Shimizu Hiroyuki and Mori Masatomo, Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084546
DOI https://dx.doi.org/10.2174/092986612802084546 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity
Current Pharmaceutical Design Inflammation Markers in Essential Hypertension
Medicinal Chemistry Psychobiome Feeding Mind: Polyphenolics in Depression and Anxiety
Current Topics in Medicinal Chemistry Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Identification of Apoptotic Drugs: Multiparametric Evaluation in Cultured Hepatocytes
Current Medicinal Chemistry Synthesis and Antiproliferative Activity of New Coumarin-Based Benzopyranone Derivatives Against Human Tumor Cell Lines
Medicinal Chemistry Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of Plant-Derived Compounds in Managing Diabetes Mellitus: A Review of Literature from 2014 To 2019
Current Medicinal Chemistry Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Recent Patents and Advances on Isolation and Cellular Therapy Applications of Mesenchymal Stem Cells from Human Umbilical Cord Whartons Jelly
Recent Patents on Regenerative Medicine Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Physiological and Pathophysiological Roles of ATP-Sensitive K+ Channels in Vascular Smooth Muscle
Vascular Disease Prevention (Discontinued) DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Metabolic Imbalance and Vitamin D Deficiency in Type 1 Diabetes in the Algerian Population
Endocrine, Metabolic & Immune Disorders - Drug Targets